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dŚĞƌĞĂƌĞĐŽŶƐŝĚĞƌĂďůĞĚŝīĞƌĞŶĐĞƐŝŶŚŽǁƉĂƟĞŶƚƐƌĞƐƉŽŶĚƚŽƚƌĞĂƚŵĞŶƚƐ
ĚƵĞƚŽĂŶƵŵďĞƌŽĨĨĂĐƚŽƌƐĐĂůůŝŶŐĨŽƌƉĞƌƐŽŶĂůŝƐĞĚĂƉƉƌŽĂĐŚĞƐƚŽĐĂƌĞ ?ǁŚŝĐŚ
ŝƐ ŚĂƉƉĞŶŝŶŐ ? ,ŽǁĞǀĞƌ ? ƚŚĞ ĞĂƌůǇ ƉƌŽŵŝƐĞ ŽĨ ƉĞƌƐŽŶĂůŝƐĞĚ ŵĞĚŝĐŝŶĞ ŚĂƐ ŶŽƚ
ĂůǁĂǇƐ ƚƌĂŶƐůĂƚĞĚ ŝŶƚŽ ŝŵƉƌŽǀĞĚ ĐĂƌĞ ĨŽƌ ƉĂƟĞŶƚƐ ? WĂǇĞƌƐ ŚĂǀĞ ĐŽŶĐĞƌŶƐ
ƚŚĂƚ ĐƵƌƌĞŶƚ ƚĞƐƚƐ ĐĂŶ ďĞ ĐŽƐƚůǇ ? ƌĞƋƵĞƐƚƐ ĨŽƌ ĨƵŶĚŝŶŐ ƐƉĞĐŝĮĐ ƚĞƐƚƐ ŚĂǀĞ
ƐƵďƐĞƋƵĞŶƚůǇ ďĞĞŶ ƌĞǀĞƌƐĞĚ ĂƐ ŵŽƌĞ ŝŶĨŽƌŵĂƟŽŶ ďĞĐŽŵĞƐ ĂǀĂŝůĂďůĞ ? ĂŶĚ
ƚŚĞƌĞŝƐĐƵƌƌĞŶƚůǇĨƌĂŐŵĞŶƚĂƟŽŶŝŶƚŚĞĨƵŶĚŝŶŐŽĨĚŝĂŐŶŽƐƟĐƚĞƐƚƐ ?WĂǇĞƌƐĂůƐŽ
ŚĂǀĞĐŽŶĐĞƌŶƐƚŚĂƚƉŚĂƌŵĂĐĞƵƟĐĂůĐŽŵƉĂŶŝĞƐĂƌĞĞǆƉůŽŝƟŶŐƚŚĞƐŝƚƵĂƟŽŶďǇ
ƐĞĞŬŝŶŐŽƌƉŚĂŶƐƚĂƚƵƐĨŽƌƚŚĞŝƌŶĞǁƚĂƌŐĞƚĞĚŵĞĚŝĐŝŶĞƐĚƌŝǀŝŶŐƵƉƌĞƋƵĞƐƚĞĚ
ƉƌŝĐĞƐ ? /ƚ ŝƐĂůƐŽŶŽƚĐůĞĂƌǁŚŽƐŚŽƵůĚĨƵŶĚďŝŽŵĂƌŬĞƌƐƚŚĂƚĂĐĐŽŵƉĂŶǇŶĞǁ
ĞǆƉĞŶƐŝǀĞ ŵĞĚŝĐŝŶĞƐ ? dŚŝƐ ŝƐ ĐŚĂŶŐŝŶŐ ĂƐ ƚŚĞ ĐŽƐƚ ŽĨ ƚĞƐƚƐ ĐŽŵĞ ĚŽǁŶ ? ĂŶĚ
ƉĂǇĞƌƐĚĞǀĞůŽƉŶĞǁŵŽĚĞůƐƚŽŽƉƟŵŝƐĞƚŚĞŵĂŶĂŐĞĚĞŶƚƌǇŽĨŶĞǁŵĞĚŝĐŝŶĞƐ
ĂƐ ǁĞůů ĂƐ ĞǀĂůƵĂƚĞ ƉŽƚĞŶƟĂů ƉƌŝĐĞƐ ĨŽƌ ŶĞǁ ŵĞĚŝĐŝŶĞƐ ĨŽƌ ŽƌƉŚĂŶ ĚŝƐĞĂƐĞƐ ?
dŚĞƌĞ ĂƌĞ ĂůƐŽ ĚĞǀĞůŽƉŵĞŶƚƐ ǁŝƚŚ  ?ďŝŐ ĚĂƚĂ ? ŽīĞƌŝŶŐ ŶĞǁƵŶĚĞƌƐƚĂŶĚŝŶŐ ŽĨ
ĚŝƐĞĂƐĞĐŽŵƉůĞǆŝƚǇƚŽĞŶŚĂŶĐĞƉŝƉĞůŝŶĞƉƌŽĚƵĐƟǀŝƚǇĂŶĚĚŝĂŐŶŽƐŝƐĂƐǁĞůůĂƐ
ŽŶŐŽŝŶŐĚĞǀĞůŽƉŵĞŶƚƐǁŝƚŚĚƌƵŐƌĞƐŝƐƚĂŶĐĞƚĞƐƟŶŐĂŶĚƌĞƐĞĂƌĐŚŝŶƚŽƚŚĞƌŽůĞ
ŽĨŵŝĐƌŽďŝŽŵĞƐƚŽŝŵƉƌŽǀĞĨƵƚƵƌĞŚĞĂůƚŚ ?ƵƌƌĞŶƚĐŚĂůůĞŶŐĞƐĂŶĚĐŽŶĐĞƌŶƐĂƌĞ
ďĞŝŶŐĂĚĚƌĞƐƐĞĚ ?dŚŝƐǁŝůůĐŽŶƟŶƵĞƚŽŝŵƉƌŽǀĞƉĂƟĞŶƚĐĂƌĞ ?
Introduction
Patients respond differently to medicines due to a variety of 
factors including biologic, environment and genetic factors1,2. A 
patients genomes account for 20-95% of the variation in response 
to drug disposition2,3, translating into considerable differences in 
response to treatments2,4,5. 
Some treatments are already targeted, e.g. tamoxifen for patients 
with breast cancer with oestrogen receptor (ER) sensitivity and 
trastuzumab for HER2 positive patients2,6. Until recently, treatment 
for patients with hepatitis C was dependent on their genotype7. This 
is changing with the development of second generation direct-acting 
antiviral agents8. 
However, the complexity of the various biological systems involved 
in different diseases2,9 helps explain why there are a high number 
of non-responders to certain medicines1,2,6, and why an appreciable 
number of medicines fail to progress beyond Phases II or III despite 
early promise10. These issues put into doubt Adaptive Licensing 
approaches until better targeting of medicines can be achieved11. 
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As knowledge of biological systems grows, drug 
pipelines should become more productive and patient care 
improve2. This helps explain why the European Commission 
is one of the leading drivers in personalised medicine in 
Europe and beyond2,12. The collection of big data offering 
new understanding of disease complexity13,14 should 
further enhance pipeline productivity. However, there 
are continuing concerns that the concept of personalised  ?
due to inherent limitations including Darwinian evolution 
resulting in intratumour heterogeneity6.   
Resource issues are important especially in Europe with 
payers increasingly unable to fund all new premium priced 
medicines15. This includes new cancer medicines and 
those for orphan diseases at ever increasing prices2,6,16-18. 
Consequently, new effective medicines or genomic tests 
that offer better targeting and reduced overall costs should 
be welcomed by all key stakeholder groups. 
2EMHFWLYHVDQGGH¿QLWLRQV
Personalised medicine and personalised healthcare 
are not new concepts2. Greater targeting of treatments has 
the potential to revolutionise healthcare delivery through 
improved effectiveness, reducing the numbers needed to 
treat (NNT), reducing side-effects increasing the numbers 
needed to harm (NNH), as well as potentially  reducing 
costs2,19. ǡ      ?ǡ  
of pharmacogenomics have not always translated into 
appreciable improvements in patient care2. In addition, 
some tests have been advocated to improve patient 
selection; however, subsequent caution is preached as 
more data becomes available2. There are also concerns that 
pharmaceutical companies are seeking orphan status for 
new targeted medicines driving up prices costs2,20,21.
Consequently, the objective of this mini review is to 
appraise current knowledge about the value and concerns 
of personalised medicine principally from a payers 
perspective to debate potential ways forward.
Key considerations
General considerations 
Greater knowledge of genomics increases the    ?    
to enhance their effectiveness and/ or reduce their 
toxicity. However, there are concerns that currently only 
a few geno- or phenotyping tests are being used routinely 
in clinical practice, exacerbated by ongoing debates2. 
Pharmacogenomics has been effective in predicting 
toxicities to treatments, e.g. abacavir in HIV type 1 patients. 
However there are concerns with the sensitivity and  ?
ȋȌ ? ?Ǧ	
(infusion or oral tablets) for the management of their GI 
cancer2. 
In cancer, Poly(adenosine diphosphateribose) 
polymerase (PARP) inhibitors have shown promise in a 
subgroup of breast cancer patients with triple negative 
breast cancer (TNBC) who have inherent defects in DNA 
repair2. However, there is ongoing debate whether the 
additon of PARP1 inhibitors to platinum agents or other 
agents, including mTOR inhibitors, will improve survival 
in TNBC patients22,23. In addition, the results from different 
targeted approaches to managing patients with cancer 
have generally been disappointing apart from a few well-
known cases6.
Biomarkers         ? 
biomarker as a biological molecule found in blood, other  ?ǡ
process, or of a condition or disease2.  They are increasingly      ?     
effectiveness2Ǥ       ?  ǡ  	     Ǥ	ǡ    
	    ?  ?   ȋ ? ? Ȃ  ? ? ?  
cancers), leading to label changes2. 
Research has also centred on identifying easy to use 
biomarkers, which along with increasing knowledge 
of gene expression and aberrant signalling pathways, 
should increase the number of medicines that can be 
rationally prescribed and dosed2. However, this is proving 
problematic6.
Challenges and concerns for routine use of diagnostic 
tests
There are ongoing controversies and concerns regarding 
the routine use and funding of some pharmacogenetic 
tests.  The EGAPP (Evaluation of Genomic Applications in 
Practice and Prevention) group in the US2,24 had concerns  ? ? ?Ǥ
There are also continuing controversies surrounding 
genetic testing prior to initiation with either clopidogrel 
or warfarin2 as well as ongoing debates about funding of 
BRCA testing and Oncotype DX testing for patients with 
breast cancer in terms of their associated costs and cost-
effectiveness. This should change with costs falling for 
pharmacogenetic testing2. These issues increase concerns 
among payers with funding new personalised medicine 
approaches including tests.This needs to be addressed.	
of single and combined biomarker test information as well 
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as developments in technology platforms, mathematical 
models, and systems biology.This may mean more complex 
and costly clinical studies posing organisational and ethical 
problems especially if multiple subgroups with different 
treatment strategies are included2,25.  One way forward 
could be to have studies combined with systems biology 
modelling including big data2,14.       ?   ǡ
velocity, variety and veracity of complex data, combining 
the generation, storage and analysis of data from health 
records, biological samples, imaging, environmental factors, 
digital biomarkers and known biological mechanisms, with 
statistical, mathematical and computational analyses14.        ?  
associations.  Knowledge, predictive models and decision 
support systems developed from these analyses could 
potentially be applied to data from an individual patient 
to allow for more personalisation in the research and 
discovery process, more precise diagnosis, and more 
personalised preventative and therapy strategies26. 
However, still concerns in patients with cancer6.
Genetic data is being generated in ever escalating 
volumes at faster speeds as a consequence of the rapidly 
evolving sequencing technology. However, a gulf has 
evolved between the speculated potential of genomic 
data and the yields that it was delivering clinically27. To 
help address this, the systems available are undergoing 
a revolution with for instance IBM Watson working with 
a number of institutions to use cognitive computing 
capability to develop OncoKB, an Oncology knowledge 
base28 to generate new understanding, diagnostic and 
treatment options for individual cancer patients. 
In addition to genetic biomarkers, high volume, high     ?  ǲǦ    ǲ29 are 
becoming increasingly available and are being exploited   Ǥ  	 ǡ  
study is a global cardiovascular research study using 
technology built on the Apple ResearchKit Platform. This 
is using a combination of mobile phone sensors and short 
questionnaires to collect data on over 50,000 participants. 
The study is now collaborating with 23andMe and 
participants have the option of sharing their genetic data 
with myHeartCounts researchers30,31.   
It will also become increasingly important for 
regulatory agenices to collaborate on the development and 
establishment of harmonised guidelines for genotyping 
and biomarker testing. However, it is acknowledged there  ?Ǥ
Key issues for healthcare and funding bodies
Key issues for payers include clearer co-ordination 
between the various bodies responsible for funding of 
care and those evaluating new treatment approaches. 
Companies also need strategies that address concerns 
among payers regarding personalised medicine to enhance 
future use2.
These concerns resulted in a number of medical, ethical, 
legal, social, economic and organisational issues that need 
to be considered by organisation when commercialising 
new  personalised medicine approaches2.  Key funding 
issues from a payers perspective include current high 
prices for new orphan medicines, with a number now 
reaching blockbuster status as a result2,32.  We are already 
seeing new medicines for orphan diseases funded at up to 
15million/ QALY following pressure on governments, and 
this cannot continue21,33.
Social issues include potential stigmatisation of 
certain subpopulations as well as reimbursement 
issues. Reimbursement issues include who should fund 
accompanying tests for new medicines if there are resource 
concerns2.
Future
There are a number of potential ways forward for all 
key stakeholder groups to enhance utilisation and funding 
for new diagnostic or prognostic tests as well as targeted 
treatment approaches, which have been summarised 
in a recent publication2. Suggested activities include re- ? 
pricing approaches, seeking more information about     ?    
reimbursement, and developing new models to optimise 
the management of new personalised treatments starting 
pre-launch and continuing post launch2,21,34.  
Patient and physician education will also be an 
increasing challenge as the range of therapeutic options       Ǥ 	
instance, a recent survey suggested only 10% of physicians 
in the US believed they were adequately informed about 
pharmacogenomic testing35, and this will grow with greater 
sophistication and more options unless address. However, 
this is likely to change as targeted therapies become more 
commonplace coupled with developments in decision 
support tools and technology platforms.
Personalised medicine for infection  Drug resistance 
testing
Conventional lab culture techniques can take several 
weeks and may not accurately capture all pathogenic Ǥ ?
polymerase chain reaction (PCR) methods, amplifying 
pre-selected resistance genes if they are present. Such 
tests can reduce diagnosis time to <1 day36. However, one 
limitation of such methods is that they are currently unable 
to detect novel resistance genes. Recent advances in Whole 
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Genome Sequencing (WGS) should help address this37, 
allowing the tracking of resistant outbreaks in hospitals38 
and the community. WGS may also allow early warning of 
resistance before it emerges39Ǥ	
the genotypes that lead to phenotypic resistance will be 
 ?
resistance development.  This is increasingly essential 
to reduce resistance rates, which is a global concern 
increasing morbidity, mortality and costs40,41. Alongside 
this, the development of new bioinformatics tools capable 
of improving data analysis42.
The role of the microbiome in personalised medicine
The role of the microbiome is also becoming increasingly 
apparent in human health43,44 especially as the microbiome 
can be cheaply and, in some cases, relatively easily, 
manipulated, in a non-invasive manner45,46. The microbiome  ?ǡǤǤ
obesity47 which is another growing global public health 
issue48, and as a non-invasive biomarker, e.g. diagnosis of 
Crohns disease49. Drug-microbiota interactions have also  ?50. 
Large-scale studies such as the Human Microbiome Project 
have extensively mapped the composition of the microbiome 
during disease states and shown the role of microbial species 
present by association. However a greater understanding of 
the mechanism of interaction between host and microbe will       ?    ?51.
Funding and other issues
Successful funding by payers of new developments 
will need to address their key concerns following the    ?   
 2. 
There will also be greater scrutiny over the value of  new 
personalised medicines including   new cancer medicines 
given ever increasing costs16-18,52,53, leading to discussions 
on minimum effectiveness criteria for these medicines16,17. 
There will also increasingly be discussions on who should 
fund companion diagnostic tests for new premium priced 
developments starting pre-launch.  
Conclusions 
Personalised medicines, including targeted treatments,     ?   
healthcare systems with increasing knowledge of genomics 
and pharmacogenomics6. 
To attain this, there must be greater co-ordination 
of bodies including payers to fund new medicines and 
diagnostic tests of value. Alongside this, greater scrutiny 
over requested prices for new targeted medicines especially 
for cancer and orphan diseases16-18,21,52. Pharmaceutical 
companies should also consider more realistic pricing 
for new targeted treatments to enhance reimbursement 
with reduced need for extensive marketing including 
advertising2,53. 
We hope this short review has stimulated further debate 
about personalised medicine and potential ways forward 
for all key stakeholder groups. 
&RQÀLFWVRI,QWHUHVW ? Ǥ
The write-up of this paper was in part supported by a grant 
from the Karolinska Institutet.
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